Effect of antidepressant drugs on veratridine-evoked glutamate and aspartate release in rat prefrontal cortex

Polish Journal of Pharmacology

Volumn 51, Issue 1, 1999, Pages 63-70

  Gołembiowska, Krystyna ^a   Zylewska, Alicja ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Citalopram; Desipramine; Glutamate and aspartate; Imipramine; Microdialysis; Rat prefrontal cortex

Indexed keywords

ANTIDEPRESSANT AGENT; ASPARTIC ACID; CITALOPRAM; DESIPRAMINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; GLUTAMIC ACID; IMIPRAMINE; NORADRENALIN; SEROTONIN 1B RECEPTOR; SODIUM CHANNEL; VERATRIDINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN PERFUSION; CONTROLLED STUDY; DOPAMINE RELEASE; INTRACEREBRAL DRUG ADMINISTRATION; MALE; MICRODIALYSIS; NEUROTRANSMITTER RELEASE; NONHUMAN; NORADRENALIN RELEASE; PREFRONTAL CORTEX; RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS; ASPARTIC ACID; CITALOPRAM; DESIPRAMINE; DOPAMINE; GLUTAMIC ACID; IMIPRAMINE; MALE; MICRODIALYSIS; NOREPINEPHRINE; PIPERAZINES; PREFRONTAL CORTEX; RATS; RATS, WISTAR; SEROTONIN AGONISTS; TIME FACTORS; VERATRIDINE;

EID: 0345369541     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Auerbach S. B., Hjorth S.: Effect of chronic administration of the selective serotonin (5-HT) uptake inhibitor citalopram on extracellular 5-HT and apparent autoreceptor sensitivity in rat forebrain in vivo. Naunyn-Schmied. Arch. Pharmacol., 1995, 352, 597-606.
2. Bannon M. J., Roth R. H.: Pharmacology of mesocortical dopamine neurons. Pharmacol. Rev., 1983, 35, 53-68.
3. Bell N., Artigas F.: In vivo effects of the simultaneous blockade of serotonin and norepinephrine transporters on serotonergic function. Microdialysis studies. J. Pharmacol. Exp. Ther., 1996, 278, 1064-1072.
4. Carboni E., Tanda G. L., Frau R., Di Chiara G.: Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J. Neurochem., 1990, 55, 1067-1070.
5. 3 receptor activation in medial prefrontal cortex of freely moving rats. Synapse, 1992, 10, 264-266.
6. Choi J. J., Huang G.-J., Shafik E., Wu W.-H., MrArdle J. J.: Imipramine's selective suppression of an L-type calcium channel in neurons of murine dorsal root ganglia involves G proteins. J. Pharmacol. Exp. Ther., 1992, 263, 49-53.
7. Cotman C. W., Monaghan D. T., Ottersen O. P., Storm-Mathisen J.: Anatomical organization of excitatory amino acid receptors and their pathways. Trends Neurosci., 1987, 10, 273-280.
8. Crowder J. M., Bradford H. F.: Inhibitory effects of noradrenaline and dopamine on calcium influx and neurotransmitter glutamate release in mammalian brain slices. Eur. J. Pharmacol., 1987, 143, 343-352.
9. Daniel W., Adamus A., Melzacka M., Szymura J.: The route of administration of imipramine as a factor affecting formation of its metabolite desipramine. J. Pharm. Pharmacol., 1982, 34, 678-680.
10. De Deurwaerd re P., Bonhomme N., Lucas G., Le Moal M., Spampinato U.: Serotonin enhances striatal dopamine outflow in vivo through dopamine uptake sites. J. Neurochem., 1996, 66, 210-215.
11. Fozard J. R.: Neuronal 5-HT receptors in the periphery. Neuropharmacology, 1984, 23, 1473-1486.
12. Glowinski J., Axelrod J.: Inhibition of uptake of tritiated-noradrenaline in the intact rat brain by imipramine and structurally related compounds. Nature, 1964, 204, 1318-1319.
13. Gobert A., Rivet J.-M., Audinot V., Newman-Tancredi A., Cistarelli L., Millan M. J.: Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto-and heteroreceptor-mediated control of release. Neuroscience, 1998, 84, 413-529.
14. Gresch P. J., Sved A. F., Zigmond M. J., Finlay J. M.: Local influence of endogenous norepinephrine on extracellular dopamine in rat medial prefrontal cortex. J. Neurochem., 1995, 65, 111-116.
15. Horger B. A., Roth R. H.: Stress and central amino acid systems. In: Neurobiological and Clinical Consequences of Stress: from Normal Adaptation to PTSD. Eds. Friedman M. J., Charney D. S., Deutch A. Y., Lippincott-Raven Publishers, Philadelphia, 1995, 61-81.
16. 2 dopaminergic receptors mediate inhibition of excitatory synaptic transmission in rat neostriatum. Brain Res., 1995, 690, 264-268.
17. Huntley G. W., Vickers J. C., Morrison J. H.: Cellular and synaptic localization of NMDA and non-NMDA receptor subunits in neocortex: organizational features related to cortical circuitry, function and disease. Trends Neurosci., 1989, 17, 536-543.
18. Imperato A., Di Chiara G.: Trans-striatal dialysis coupled to reverse phase high performance liquid chromatography with electrochemical detection: a new method for the study of the in vivo release of endogenous dopamine and metabolites. J. Neurosci., 1984, 4, 966-977.
19. +-channels. Eur. J. Pharmacol., 1992, 221, 377-380.
20. Iyer R. N., Bradberry C. W.: Serotonin-mediated increase in prefrontal cortex dopamine release: pharmacological characterization. J. Pharmacol. Exp. Ther., 1996, 277, 40-47.
21. 3H)-dopamine via reversal of the dopamine transporter in rat striatum and nucleus accumbens: a comparison with release elicited by potassium, N-methyl-D-aspartic acid, glutamic acid and d-amphetamine. J. Pharmacol. Exp. Ther., 1992, 262, 356-364.
22. + efflux in cultured spinal cord neurons. Brain Res., 1991, 545, 59-65.
23. Kamisaki Y., Hamahashi T., Okada C. M., Itoh T.: Clonidine inhibition of potassium-evoked release of glutamate and aspartate from rat cortical synaptosomes. Brain Res., 1991, 568, 193-198.
24. Kitamura Y., Zhao X.-H., Takei M., Yonemitsu O., Nomura Y.: Effects of antidepressants on the glutamatergic system in mouse brain. Neurochem. Int., 1991, 19, 247-253.
25. Knecht R., Chang J.-Y.: Liquid chromatographic determination of amino acids after gas-phase hydrolysis and derivatization with (dimethylamino) azobenzenesulfonyl chloride. Anal. Chem., 1986, 58, 2375-2379.
26. Leander J. D.: Tricyclic antidepressants block N-methyl-D-aspartic acid-induced lethality in mice. Brit. J. Pharmacol., 1989, 96, 256-258.
27. 2-adrenoceptors in the central nervous system. J. Physiol. Pharmacol., 1995, 46, 241-258.
28. Maj J.: Antidepressant drugs: will new findings change the present theories of their action? Trends Pharmacol. Sci., 1981, 4, 80-83.
29. Martin G. R., Humprey P. P. A.: Receptors for 5-hydroxytryptamine: current perspectives on classification and nomenclature. Neuropharmacology, 1994, 33, 261-273.
30. Maycox P. R., Hell J. W., Jahn R.: Amino acids neurotransmission: spotlight on synaptic vesicles. Trends Neurosci., 1990, 13, 83-87.
31. McQuade R., Sharp T.: Functional mapping of dorsal and median raphe 5-hydroxytryptamine pathways in forebrain of the rat using microdialysis. J. Neurochem., 1997, 69, 791-796.
32. Nicholls D. G.: Release of glutamate, aspartate, and gamma-aminobutyric acid from isolated nerve terminals. J. Neurochem., 1989, 52, 331-341.
33. Nowak G., Legutko B., Skolnick P., Popik P.: Adaptation of cortical NMDA receptors by chronic treatment with specific serotonin reuptake inhibitors. Eur. J. Pharmacol., 1998, 342, 367-370.
34. Nowak G., Ordway G. A., Paul I. A.: Alterations in N-methyl-D-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res., 1995, 675, 157-164.
35. Owens M. J., Morgan W. N., Plott S. J., Nemeroff C. B.: Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J. Pharmacol. Exp. Ther., 1997, 283, 1305-1322.
36. + channels by antidepressant drugs. J. Pharmacol. Exp. Ther., 1998, 284, 208-214.
37. Paul I. A., Nowak G., Layer R. T., Popik P., Skolnick P.: Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. J. Pharmacol. Exp. Ther., 1994, 269, 95-102.
38. Paxinos G., Watson C.: The Rat Brain in Stereotaxic Coordinates. Academic Press, San Diego, 1998.
39. Reynolds I. J., Miller R J.: Tricyclic antidepressants block N-methyl-D-aspartate receptors: similarities to the action of zinc. Brit. J. Pharmacol., 1988, 95, 95-102.
40. Ross S. B., Renyi A. L.: Inhibition of the uptake of tritiated 5-hydroxytryptamine in brain tissue. Eur. J. Pharmacol., 1969, 7, 270-277.
41. Seeman P., Van Tol H. M.: Dopamine receptor pharmacology. Trends Pharmacol. Sci., 1994, 15, 264-270.
42. Séguéla P., Watkins K. C., Geffard M., Descarries L.: Noradrenaline axon terminals in adult rat neocortex: an immunocytochemical analysis in serial thin sections. Neuroscience, 1990, 35, 249-264.
43. Sernagor E., Kuhn D., Vyklicky L. Jr., Mayer M. L.: Open channel block of NMDA receptor responses evoked by tricyclic antidepressants. Neuron, 1989, 2, 1221-1227.
44. 2+ in veratridine-induced glutamate release. NeuroReport, 1996, 7, 401-404.
45. Tanda G., Carboni E., Frau R., Di Chiara G.: Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential? Psychopharmacology, 1994, 115, 285-288.
46. 3 receptors mediate fluoxetine but not desipramine-induced increase of extracellular dopamine in the prefrontal cortex. Psychopharmacology, 1995, 119, 15-19.
47. Trullas R., Skolnick P.: Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur. J. Pharmacol., 1990, 185, 1-10.
48. Yamamoto B. K., Novotney S.: Regulation of extracellular dopamine by the norepinephrine transporter. J. Neurochem., 1998, 71, 274-280.